Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Diwakar Davar"'
Autor:
Andres Forero-Torres, Ecaterina Ileana Dumbrava, Rachel E. Sanborn, Elena Garralda, Alex F. Herrera, Giuseppe Curigliano, Vincent Ribrag, Diwakar Davar, Amitkumar Mehta, Carmen Belli, Stephen M. Ansell, Honey Kumar Oberoi, Clémentine Sarkozy, Jasmine Zain
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundT-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory domains (TIGIT), and costimulatory receptor CD226 competitively bind 2 ligands, CD155 and CD112, which are expressed by tumor cells and antigen-presentin
Autor:
Alan J. Korman, Diwakar Davar, Cindy Sander, Mignane B. Ka, John M. Kirkwood, Julien Fourcade, Hassane M. Zarour, Hong Wang, Ornella Pagliano, Zhaojun Sun, Joe-Marc Chauvin, Sofiane Saada, Carmine Menna, Rada Amin
CD4+ Tregs impede T cell responses to tumors. They express multiple inhibitory receptors that support their suppressive functions, including T cell Ig and ITIM domain (TIGIT). In melanoma patients, we show that Tregs exhibit increased TIGIT expressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b285657653ceffba41ce16464236057
https://europepmc.org/articles/PMC6124410/
https://europepmc.org/articles/PMC6124410/
Autor:
Carmine Menna, Amirin Dzutsev, Marie Vétizou, Jonathan H. Badger, John M. Kirkwood, John McCullogh, Hassane M. Zarour, Giorgio Trinchieri, Diwakar Davar, Ornella Pagliano
Publikováno v:
Cancer Immunology Research. 7:IA38-IA38
Immunotherapy with blocking anti-PD1 monoclonal antibodies (a PD1 mAbs) has become one of the most potent therapies of melanoma, providing extended clinical benefits to 30-40% advanced melanoma patients. There is substantial evidence that pre-existin